Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAREEN DARANEE SIRI

Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology

NPI
1730272998
CMS profile
33612
Location
NORMAL, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$234,819.98

320 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAREEN DARANEE SIRI

NPI 1730272998 · CMS profile ID 33612

Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology

NORMAL, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAREEN DARANEE SIRI, NPI 1730272998, CMS profile ID 33612. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DAREEN DARANEE SIRI, NPI 1730272998, CMS profile ID 33612. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DAREEN DARANEE SIRI, NPI 1730272998, CMS profile ID 33612, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

320 matching records · $234,819.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 320 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 320.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dermavant Sciences, Inc. $317.3910/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127935407 CMS
Dermavant Sciences, Inc. $197.0010/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127935411 CMS
Dermavant Sciences, Inc. $69.1410/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127935415 CMS
Dermavant Sciences, Inc. $32.0010/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127935419 CMS
Dermavant Sciences, Inc. $658.4210/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127935423 CMS
Organon LLC $6,360.0010/24/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1239012453 CMS
Organon LLC $47.3710/24/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1239012455 CMS
Organon LLC $205.7310/24/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1239012457 CMS
Organon LLC $317.3910/24/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1239012459 CMS
Organon LLC $197.0010/24/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1239012461 CMS
Organon LLC $1,313.7510/24/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1239012463 CMS
Organon LLC $607.9910/24/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1239012465 CMS
Organon LLC $658.4210/24/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1239012467 CMS
GENZYME CORPORATION $2,447.0010/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139741064 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.7210/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137677493 CMS
ADMA BioManufacturing LLC $122.4310/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149638950 CMS
Pharming Healthcare, Inc. $19.0310/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132166021 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.6810/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137677491 CMS
Pharming Healthcare, Inc. $1,800.0010/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132166014 CMS
ADMA BioManufacturing LLC $85.3710/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149638946 CMS
ADMA BioManufacturing LLC $31.4610/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639242 CMS
ADMA BioManufacturing LLC $1,125.0010/10/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639868 CMS
ADMA BioManufacturing LLC $150.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639898 CMS
ADMA BioManufacturing LLC $626.6610/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639900 CMS
ADMA BioManufacturing LLC $286.8310/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639902 CMS
ADMA BioManufacturing LLC $509.6410/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639904 CMS
ADMA BioManufacturing LLC $332.3110/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639906 CMS
ADMA BioManufacturing LLC $4,000.0010/10/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639908 CMS
GENZYME CORPORATION $15.9410/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139741046 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.2310/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137677489 CMS
GlaxoSmithKline, LLC. $3.4010/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116503259 CMS
Octapharma USA, Inc. $74.7410/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142319397 CMS
Pharming Healthcare, Inc. $24.1610/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132166005 CMS
Regeneron Healthcare Solutions, Inc. $133.6209/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114177143 CMS
Regeneron Healthcare Solutions, Inc. $133.6209/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114177148 CMS
Regeneron Healthcare Solutions, Inc. $0.9509/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114177152 CMS
Regeneron Healthcare Solutions, Inc. $2.8509/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114177157 CMS
Regeneron Healthcare Solutions, Inc. $146.0009/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114177162 CMS
Regeneron Healthcare Solutions, Inc. $22.9209/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114177166 CMS
GlaxoSmithKline, LLC. $3,900.0009/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116263023 CMS
PFIZER INC. $6.1209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131868338 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.9109/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137677485 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.5009/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137677487 CMS
CSL Behring $23.9309/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134606135 CMS
AstraZeneca Pharmaceuticals LP $27.8509/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104612746 CMS
Regeneron Healthcare Solutions, Inc. $524.0009/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114177139 CMS
ABBVIE INC. $3,300.0009/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106114903 CMS
ADMA BioManufacturing LLC $210.5009/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149640048 CMS
ADMA BioManufacturing LLC $707.4309/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149640050 CMS
ADMA BioManufacturing LLC $2,500.0009/13/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149640052 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $179,324.42 352
PY2020 $109,401.69 196
PY2021 $134,724.87 221
PY2022 $258,274.19 323
PY2023 $202,969.96 272
PY2024 $234,819.98 320
PY2025 $376,990.48 406

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $465,489.09 126
PY2024 Recipient $4,750.00 1
PY2024 Principal investigator $767,140.75 233
PY2023 Recipient $22,816.68 41
PY2023 Principal investigator $455,953.44 86
PY2022 Principal investigator $409,335.19 101
PY2021 Principal investigator $469,407.19 100
PY2020 Principal investigator $805,855.03 139
PY2019 Principal investigator $1,020,435.46 145

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

126 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 12/24/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184280226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 12/19/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 12/19/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 12/19/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278566
Principal investigator 1 SANOFI US SERVICES INC. $4,894.20 12/08/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082831
Principal investigator 1 ABBVIE INC. $2,423.80 12/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202527534
Principal investigator 1 Incyte Corporation $1,459.00 12/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591720
Principal investigator 1 Incyte Corporation $1,908.00 12/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 11/19/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,362.12 11/19/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 11/19/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262455
Principal investigator 1 ABBVIE INC. $1,807.19 11/05/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202522697
Principal investigator 1 Incyte Corporation $1,479.60 11/05/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591731
Principal investigator 1 GlaxoSmithKline, LLC. $928.80 10/23/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192188087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,377.42 10/17/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 10/17/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,359.58 10/17/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,377.42 10/17/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251355
Principal investigator 1 SANOFI US SERVICES INC. $2,257.30 10/14/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082810
Principal investigator 1 ABBVIE INC. $2,505.25 10/09/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202515077
Principal investigator 1 GlaxoSmithKline, LLC. $377.50 10/02/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192098294
Principal investigator 1 Incyte Corporation $1,585.80 10/02/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591724
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,356.78 10/01/2025 Non-covered Recipient Entity
MIDWEST ALLERGY SINUS ASTHMA, SC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190308410
Principal investigator 1 SANOFI US SERVICES INC. $4,326.00 09/22/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082794
Principal investigator 1 ABBVIE INC. $1,000.00 09/15/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 09/15/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 09/15/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 09/15/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,323.88 09/15/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237474
Principal investigator 1 ABBVIE INC. $2,334.63 09/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202509756
Principal investigator 1 Incyte Corporation $48.60 09/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591696
Principal investigator 1 Incyte Corporation $1,644.00 09/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591701
Principal investigator 1 Incyte Corporation $1,644.00 09/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591705
Principal investigator 1 Incyte Corporation $3,590.00 09/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591709
Principal investigator 1 Incyte Corporation $3,590.00 09/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591712
Principal investigator 1 Incyte Corporation $3,590.00 09/04/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240591716
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 09/01/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223284667
Principal investigator 1 SANOFI US SERVICES INC. $2,271.30 08/25/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,973.81 08/21/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184229505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,706.95 08/21/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184229507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,413.12 08/21/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184229509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 08/21/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184229511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 08/21/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184229513
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,500.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1185545571
Principal investigator 1 GlaxoSmithKline, LLC. $2,350.00 08/20/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192098280
Principal investigator 1 GlaxoSmithKline, LLC. $12,255.00 08/20/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192098287
Principal investigator 1 GlaxoSmithKline, LLC. $975.00 08/20/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192189172
Principal investigator 1 ABBVIE INC. $1,980.25 08/06/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202502370
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $175.00 08/01/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223283307
Principal investigator 1 SANOFI US SERVICES INC. $2,257.30 07/28/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082738
Principal investigator 1 GlaxoSmithKline, LLC. $2,464.20 07/23/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192098307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,307.40 07/22/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282920
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,910.28 07/21/2025 Non-covered Recipient Entity
MIDWEST ALLERGY SINUS ASTHMA, SC
A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy. No dispute reported 06/30/2026 1190311631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,413.12 07/14/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184214896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 07/14/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184214898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.00 07/14/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184214900
Principal investigator 1 ABBVIE INC. $3,669.91 07/02/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202494995
Principal investigator 1 Novartis Pharmaceuticals Corporation $237.00 07/01/2025 Non-covered Recipient Entity
MIDWEST ALLERGY SINUS ASTHMA, SC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190311629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 06/27/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 06/27/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 06/27/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,362.12 06/27/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,362.12 06/27/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211801
Principal investigator 1 GlaxoSmithKline, LLC. $5,089.50 06/20/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192098300
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,270.50 06/19/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281622
Principal investigator 1 SANOFI US SERVICES INC. $2,773.00 06/16/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082691
Principal investigator 1 PFIZER INC. $1,000.00 06/14/2025 Non-covered Recipient Entity
Midwest Allergy Sinus Asthma SC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228792194
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,970.80 06/12/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281092
Principal investigator 1 ABBVIE INC. $7,902.58 06/03/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202488389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.90 05/22/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280126
Principal investigator 1 GlaxoSmithKline, LLC. $2,516.40 05/21/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192189164
Principal investigator 1 SANOFI US SERVICES INC. $10,650.00 05/19/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082703
Principal investigator 1 UCB SA $1,500.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657196
Principal investigator 1 UCB SA $14,000.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657200
Principal investigator 1 UCB SA $500.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657212
Principal investigator 1 UCB SA $500.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657216
Principal investigator 1 UCB SA $1,000.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657247
Principal investigator 1 UCB SA $1,500.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657250
Principal investigator 1 UCB SA $2,000.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657253
Principal investigator 1 UCB SA $7,000.00 05/09/2025 Non-covered Recipient Entity
Sneeze, Wheeze And Itch Associates, Llc
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,359.58 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,706.95 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,323.88 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,973.81 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,323.88 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,359.58 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.00 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.20 04/28/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190493
Principal investigator 1 Amgen Inc. $10,880.00 04/23/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246648290
Principal investigator 1 GlaxoSmithKline, LLC. $5,840.10 04/23/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192189160
Principal investigator 1 GlaxoSmithKline, LLC. $8,820.00 04/16/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192189168
Principal investigator 1 Eli Lilly and Company $1,672.20 04/10/2025 Non-covered Recipient Entity
SNEEZE, WHEEZE & ITCH ASSOCIATES
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187888628
Principal investigator 1 SANOFI US SERVICES INC. $17,022.00 04/07/2025 Non-covered Recipient Entity
Sneeze Wheeze Itch Associates
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082625
Principal investigator 1 ABBVIE INC. $12,040.00 04/03/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202468907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 04/01/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223277200
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.90 04/01/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223277250
Principal investigator 1 Incyte Corporation $698.26 03/27/2025 Non-covered Recipient Entity
DIRECT HELPERS RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240528791
Principal investigator 1 PFIZER INC. $1,666.60 03/22/2025 Non-covered Recipient Entity
Midwest Allergy Sinus Asthma SC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228780837
Principal investigator 1 GlaxoSmithKline, LLC. $3,055.72 03/20/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192188080
Principal investigator 1 GlaxoSmithKline, LLC. $12,250.00 03/20/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192188091
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,800.60 03/11/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223276167
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,516.45 02/26/2025 Non-covered Recipient Entity
SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185545569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,706.95 02/26/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184155668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.00 02/26/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184155670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,973.81 02/26/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184155672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.00 02/26/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184155674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.00 02/26/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184155676
Principal investigator 1 GlaxoSmithKline, LLC. $3,327.30 02/25/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192098313
Principal investigator 1 Incyte Corporation $1,441.80 02/19/2025 Non-covered Recipient Entity
DIRECT HELPERS RESEARCH CENTER
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240528774
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,190.70 01/31/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185545573
Principal investigator 1 GlaxoSmithKline, LLC. $1,527.86 01/30/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192188084
Principal investigator 1 Amgen Inc. $64,847.75 01/29/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648286
Principal investigator 1 Amgen Inc. $44,678.26 01/27/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246648282
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 01/27/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274503
Principal investigator 1 GlaxoSmithKline, LLC. $5,350.50 01/24/2025 Non-covered Recipient Entity
SNEEZE WHEEZE ITCH ASSOCIATES
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192098320
Principal investigator 1 Incyte Corporation $5,575.15 01/23/2025 Non-covered Recipient Entity
DIRECT HELPERS RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240528786
Principal investigator 1 Incyte Corporation $67.50 01/17/2025 Non-covered Recipient Entity
DIRECT HELPERS RESEARCH CENTER
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240528782
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $175.00 01/16/2025 Non-covered Recipient Entity
SNEEZE WHEEZE & ITCH ASSOCIATES
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223273945
Principal investigator 1 PFIZER INC. $9,999.60 01/15/2025 Non-covered Recipient Entity
Midwest Allergy Sinus Asthma SC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228798760
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,429.90 01/07/2025 Non-covered Recipient Entity
SNEEZE WHEEZE AND ITCH ASSOCIATES LLC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223273613
Principal investigator 1 Incyte Corporation $168.00 01/02/2025 Non-covered Recipient Entity
DIRECT HELPERS RESEARCH CENTER
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240528770
Principal investigator 1 Incyte Corporation $470.82 01/02/2025 Non-covered Recipient Entity
DIRECT HELPERS RESEARCH CENTER
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240528778
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,216.25 01/01/2025 Non-covered Recipient Entity
MIDWEST ALLERGY SINUS ASTHMA SC
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190306595

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $34,237.50 1
PY2025 Value of interest $34,237.50 1
PY2024 Amount invested $34,237.50 1
PY2024 Value of interest $34,237.50 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2024–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Consortium of Independent Immunology Clinics, LLC $34,237.50 $34,237.50 n/a Physician Covered Recipient No dispute reported 06/30/2026 1228219705
PY2024 Consortium of Independent Immunology Clinics, LLC $34,237.50 $34,237.50 n/a Physician Covered Recipient No dispute reported 06/30/2026 1147193724